BIO 11006

Drug Profile

BIO 11006

Alternative Names: BIO-11006; BIO-11006 Inhalation Solution

Latest Information Update: 24 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator North Carolina State University
  • Developer BioMarck Pharmaceuticals
  • Class Antineoplastics; Expectorants; Peptides
  • Mechanism of Action Myristoylated alanine rich C kinase substrate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Non-small cell lung cancer
  • Clinical Phase Unknown Lung cancer
  • Preclinical Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma

Most Recent Events

  • 23 Jan 2018 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease) in India (Inhalation) (CTRI/2018/01/011152)
  • 02 Nov 2017 BioMark initiates enrolment in a phase II trial for Adult respiratory distress syndrome in USA (Inhalation) before November 2017 (NCT03202395)
  • 05 Aug 2017 Phase-II clinical trials in Adult respiratory distress syndrome in USA (Inhalation) (NCT03202394)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top